Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone

Oncology (Williston Park). 2018 May 15;32(5):223, 226-7, 247.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abiraterone Acetate / adverse effects
  • Abiraterone Acetate / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Clinical Decision-Making
  • Docetaxel
  • Humans
  • Male
  • Neoplasm Metastasis
  • Patient Selection
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Risk Factors
  • Steroid Synthesis Inhibitors / adverse effects
  • Steroid Synthesis Inhibitors / therapeutic use*
  • Taxoids / adverse effects
  • Taxoids / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Steroid Synthesis Inhibitors
  • Taxoids
  • Docetaxel
  • Abiraterone Acetate